Skip to main content

Ketamine Injection Shortage

Last Updated: March 24, 2025
Status: Current

Products Affected - Description
    • Ketalar injection, Par Pharmaceuticals, 100 mg/mL, 5 mL vial, 10 count, NDC 42023-0115-10
    • Ketalar injection, Par Pharmaceuticals, 50 mg/mL, 10 mL vial, 10 count, NDC 42023-0114-10
    • Ketamine injection, Eugia US, 100 mg/mL, 10 mL vial, 10 count, NDC 55150-0440-10
    • Ketamine injection, Eugia US, 50 mg/mL, 10 mL vial, 10 count, NDC 55150-0439-10
    • Ketamine injection, Pfizer, 50 mg/mL, 10 mL vial, 10 count, NDC 00409-2053-10
Reason for the Shortage
    • AuroMedics (Eugia) has ketamine on shortage due to increased demand.
    • Hikma has ketamine injection available.
    • Mylan Institutional divested ketamine to AuroMedics.
    • Par has Ketalar on back order due to shortage of active ingredient.
    • Pfizer has ketamine on shortage due to manufacturing delays.
    • Sagent has ketamine injection available.
Available Products
    • Ketalar injection, Par Pharmaceuticals, 10 mg/mL, 20 mL vial, 10 count, NDC 42023-0113-10
    • Ketamine injection, Eugia US, 10 mg/mL, 20 mL vial, 10 count, NDC 55150-0438-10
    • Ketamine injection, Hikma, 100 mg/mL, 5 mL vial, 10 count, NDC 00143-9509-10
    • Ketamine injection, Hikma, 50 mg/mL, 10 mL vial, 10 count, NDC 00143-9508-10
    • Ketamine injection, Pfizer, 100 mg/mL, 5 mL vial, 10 count, NDC 00409-2051-05
    • Ketamine injection, Sagent, 10 mg/mL, 20 mL vial, 10 count, NDC 25021-0682-20
    • Ketamine injection, Sagent, 100 mg/mL, 5 mL vial, 10 count, NDC 25021-0684-05
    • Ketamine injection, Sagent, 50 mg/mL, 10 mL vial, 10 count, NDC 25021-0683-10

Estimated Resupply Dates

    • Eugia has ketamine 50 mg/mL 10 mL vials and 100 mg/mL 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Pfizer has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of December 2026.
    • Par has Ketalar 50 mg/mL 10 mL vials and 100 mg/mL 5 mL vial on back order and the company cannot estimate a release date.

Implications for Patient Care

    • Ketamine is an injectable anesthetic used for the induction of general anesthesia as well as supplementation to other anesthetic agents. It is also used as a single anesthetic agent for procedures that do not require relaxation of skeletal muscles.[1]

Safety

    • Ketamine is beneficial in its hemodynamic stability; when considering alternatives, it is important to be aware of possible changes to hemodynamics.[2]

Alternative Agents & Management

    • Etomidate and propofol are common alternatives for ketamine. There are practice guidelines available for moderate procedural sedation and analgesia. These are available at https://pubs.asahq.org/anesthesiology/article/128/3/437/18818/Practice-Guidelines-for-Moderate-Procedural.

References

    1. Ketamine hydrochloride [prescribing information]. Lake Forest, IL: Hospira Inc; July 2022.
    2. Jellish WS, Edelstein S. Chapter 106 - Neuroanesthesia. In: Biller J, Ferro JM, eds. Handbook of Clinical Neurology. Vol 121. Neurologic Aspects of Systemic Disease Part III. Elsevier; 2014:1623-1633. doi:10.1016/B978-0-7020-4088-7.00106-1

Updated

Updated March 24, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.